Radek Spisek spends much of his time researching Immunology, Immune system, Immunogenic cell death, Cancer cell and Immunotherapy. His research integrates issues of Cytotoxic T cell and CD40 in his study of Immunology. The concepts of his Immune system study are interwoven with issues in Monoclonal antibody, Cytokine, Antigen and Cell biology.
His Immunogenic cell death research is multidisciplinary, incorporating perspectives in Calreticulin, Mitoxantrone and Doxorubicin. His work deals with themes such as Acquired immune system and Translational medicine, which intersect with Cancer cell. As part of one scientific family, Radek Spisek deals mainly with the area of Cancer immunotherapy, narrowing it down to issues related to the Cancer research, and often T lymphocyte.
Radek Spisek mainly focuses on Immune system, Immunology, Cancer research, Immunotherapy and Cancer. His research in Immune system intersects with topics in Cancer cell and Antigen. As a part of the same scientific study, he usually deals with the Cancer cell, concentrating on Calreticulin and frequently concerns with CD86 and Interferon.
His research brings together the fields of CD40 and Immunology. His Cancer research research includes elements of Cytotoxic T cell, Receptor, CD8 and Cancer immunotherapy. His Immunotherapy research incorporates elements of Clinical trial, Lung cancer, Oncology, Urology and Interleukin 12.
His primary areas of study are Immune system, Cancer research, Cancer cell, Tumor microenvironment and CD8. His Immune system research is multidisciplinary, incorporating elements of Oncology, Cytokine and Antigen. His Cancer research study combines topics in areas such as Cytotoxic T cell, Receptor and Cytokine milieu.
Radek Spisek studies Cancer cell, focusing on Immunogenic cell death in particular. His Central tolerance study is concerned with the field of Immunology as a whole. His biological study deals with issues like Mesenchymal stem cell, which deal with fields such as Diabetes mellitus.
Radek Spisek focuses on Immune system, Cancer research, Immunogenic cell death, Acquired immune system and Immunotherapy. His Immune system research is within the category of Immunology. His Immunology study incorporates themes from Diabetes mellitus, Glycation, Insulin and Pancreas.
He has researched Cancer research in several fields, including Immune checkpoint, Cytotoxic T cell, Calreticulin and CD20. His studies deal with areas such as Adjuvanticity, Neuroscience and Antigen presentation as well as Acquired immune system. His work carried out in the field of Immunotherapy brings together such families of science as Cytokine, Clinical trial and Oncology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Consensus guidelines for the detection of immunogenic cell death
Oliver Kepp;Laura Senovilla;Ilio Vitale;Erika Vacchelli.
Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications.
Radek Spisek;Anna Charalambous;Amitabha Mazumder;David H. Vesole.
Classification of current anticancer immunotherapies
Lorenzo Galluzzi;Erika Vacchelli;José Manuel Bravo-San Pedro;Aitziber Buqué.
Human Tumor Cells Killed by Anthracyclines Induce a Tumor-Specific Immune Response
Jitka Fucikova;Petra Kralikova;Anna Fialova;Tomas Brtnicky.
Cancer Research (2011)
Combinatorial Strategies for the Induction of Immunogenic Cell Death
Lucillia Bezu;Ligia C. Gomes-de-Silva;Heleen Dewitte;Karine Breckpot.
Frontiers in Immunology (2015)
Dendritic cells are specialized accessory cells along with TGF-β for the differentiation of Foxp3 + CD4 + regulatory T cells from peripheral Foxp3 − precursors
Sayuri Yamazaki;Anthony J. Bonito;Radek Spisek;Madhav Dhodapkar.
Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death
Abhishek D. Garg;Lorenzo Galluzzi;Lionel Apetoh;Lionel Apetoh;Thais Baert.
Frontiers in Immunology (2015)
Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy.
Jonathan Pol;Erika Vacchelli;Fernando Aranda;Francesca Castoldi.
Glucocorticoids severely impair differentiation and antigen presenting function of dendritic cells despite upregulation of Toll-like receptors
Daniela Rozkova;Rudolf Horvath;Jirina Bartunkova;Radek Spisek.
Clinical Immunology (2006)
Frequent and specific immunity to the embryonal stem cell–associated antigen SOX2 in patients with monoclonal gammopathy
Radek Spisek;Anjli Kukreja;Lin-Chi Chen;Phillip Matthews.
Journal of Experimental Medicine (2007)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: